Maynard Um
-
-
-
-
-
-
-
Beam Therapeutics (BEAM) Reiterated at Overweight by Cantor Fitzgerald
-
-
-
-
-
-
-
FDA Clears Way for Faster Personalized Gene Editing Treatments
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)
-
-
-
-
-
-
-
Beam (BEAM) Announces U.S. FDA RMAT Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency
-
-
-
-
-
-
-
Bernstein SocGen Group Reiterates Outperform Rating on Beam Therapeutics Inc (BEAM)
-
-
-
-
-
-
-
Scotiabank Upgrades Beam Therapeutics Inc (BEAM) to Sector Outperform
-
-
-
-
-
-
-
BMO Capital on Beam Therapeutics Inc (BEAM): 'AATD Readout in 1H25 Could Move BEAM 50-100%+'
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

